BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: GlobeNewswire
Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 and mRNA cancer immunotherapies Multiple data readouts expected in 2025 and 2026 aimed at providing clinical proof of BioNTech’s pipeline strategy and advancing the Company towards becoming a diversified multi-product oncology portfolio company by 2030 Completed acquisition of Biotheus securing full control of next-generation immunomodulator candidate BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1 Successfully launched JN.1- and KP.2-adapted COVID-19 vaccines across different countries and regions and maintained global
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech SE (NASDAQ: BNTX) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $145.00 price target on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its price target lowered by analysts at Morgan Stanley from $145.00 to $139.00. They now have an "overweight" rating on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $171.44 price target on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its price target raised by analysts at BMO Capital Markets from $130.00 to $143.00. They now have an "outperform" rating on the stock.MarketBeat
- BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025GlobeNewswire
BNTX
Earnings
- 3/10/25 - Beat
BNTX
Sec Filings
- 3/10/25 - Form 20-F
- 3/10/25 - Form 6-K
- 3/4/25 - Form 6-K
- BNTX's page on the SEC website